Production (Stage)
Alnylam Pharmaceuticals, Inc.
ALNY
$314.94
-$7.70-2.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.82% | 39.24% | -175.51% | 93.88% | 62.13% |
| Total Depreciation and Amortization | 6.57% | -8.11% | 14.90% | 5.31% | -48.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 78.68% | 13.65% | -40.03% | 28.40% | 17.25% |
| Change in Net Operating Assets | -100.12% | -239.25% | 20.38% | -176.35% | -25.91% |
| Cash from Operations | -45.14% | -217.71% | -87.84% | 310.49% | 51.03% |
| Capital Expenditure | 30.86% | 40.60% | 75.47% | 49.63% | 6.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 324.60% | 80.56% | -511.79% | 482.26% | 12.32% |
| Cash from Investing | 268.25% | 78.01% | -181.03% | 489.53% | 11.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 90.90% | 17.43% | 335.54% | 168.81% | -38.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -273.03% | -163.37% | -163.37% | -132.05% | -23.70% |
| Cash from Financing | 52.48% | -20.98% | 210.08% | 146.27% | -37.65% |
| Foreign Exchange rate Adjustments | 241.41% | -258.49% | 330.36% | -2,300.00% | -556.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 141.18% | 39.25% | -65.01% | 2,084.58% | 32.95% |